In Switzerland, liver cancer is among the most common cancer diagnosis and ranks in sixth place as cause of cancer-related death.¹ The risk population for hepatocellular carcinoma (HCC) will continue to rise in the future as cases of MASH (Metabolic Dysfunction-Associated Steatohepatitis) increase. The 5-year survival rate for late-stage diagnosis is less than 5%, whereas it can rise to 40-70% with early detection. However, conventional screening methods for early detection of HCC have limited sensitivity.^2,3

GAAD is a multivariate index assay that combines the results of the AFP and PIVKA-II assays with information on gender and age. It serves as an aid in the diagnosis of hepatocellular carcinoma in both early and advanced stages.^4,5

Using the GAAD algorithm alone increases the sensitivity for detecting earlystage HCC to 73%; when combined with an ultrasound, it increases to 88%.⁶ 

GAAD must be interpreted in conjunction with other diagnostic findings and clinical information according to standard clinical management guidelines.

A pilot project is running until mid March this year. If certain requirements are met, you can request a GAAD risk calculation free of charge until March 19th, 2025 and send your patient samples to our partner laboratory Bioanalytika in Lucerne.

If you would like to find out more about GAAD or on the conditions of participation, please do not hesitate to contact Dr Benjamin Eggerschwiler by e-mail benjamin.eggerschwiler.be1@roche.com or by phone on +41 79 741 66 43.